Literature DB >> 7604888

Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer.

D Mirchandani1, J Zheng, G J Miller, A K Ghosh, D K Shibata, R J Cote, P Roy-Burman.   

Abstract

Prostatic carcinoma from 65 patients have been examined for the occurrence of point mutations in the p53 tumor suppressor gene locus within the region of exons 5 to 8. Overall, only a small fraction of tumors (12.3%) was found to contain p53 mutations. No significant correlation was detected between the presence of the mutant gene and either tumor volume or histopathological grade. However, metastatic prostatic tumors are found to display a higher percentage (21.4%) of p53 mutations compared with primary adenocarcinomas (9.8%). Analysis of the topographical distribution of the p53 mutant genotype revealed two remarkable findings. First, multifocal tumors within a prostate appear to differ in harboring the mutant gene, and second, evidence is obtained for intratumor heterogeneity in the distribution of the mutant p53 allele. Together these findings appear to explain, at least in part, why there has been a wide discrepancy in the reported detection frequency of p53 mutations in prostate cancer specimens. It appears that the outcome of mutation analysis would depend not only on which tumors but also which regions of the tumors are included in the study. Furthermore, the observed heterogeneous topographical distribution of the mutation, if confirmed to be unique to prostate cancer, may have important implications in the understanding of the biology of prostate carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7604888      PMCID: PMC1869872     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.

Authors:  G Gaidano; P Ballerini; J Z Gong; G Inghirami; A Neri; E W Newcomb; I T Magrath; D M Knowles; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

Review 2.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

3.  Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation.

Authors:  T Visakorpi; O P Kallioniemi; A Heikkinen; T Koivula; J Isola
Journal:  J Natl Cancer Inst       Date:  1992-06-03       Impact factor: 13.506

Review 4.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

Review 5.  TP53 tumor suppressor gene: a model for investigating human mutagenesis.

Authors:  C Caron de Fromentel; T Soussi
Journal:  Genes Chromosomes Cancer       Date:  1992-01       Impact factor: 5.006

6.  Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration.

Authors:  G J Miller; J M Cygan
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

7.  Alterations of the P53 gene are associated with the progression of a human prostate carcinoma.

Authors:  P J Effert; A Neubauer; P J Walther; E T Liu
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

8.  Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles.

Authors:  W B Isaacs; B S Carter; C M Ewing
Journal:  Cancer Res       Date:  1991-09-01       Impact factor: 12.701

9.  Allelic loss of chromosomes 16q and 10q in human prostate cancer.

Authors:  B S Carter; C M Ewing; W S Ward; B F Treiger; T W Aalders; J A Schalken; J I Epstein; W B Isaacs
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

10.  Detection of human papilloma virus in paraffin-embedded tissue using the polymerase chain reaction.

Authors:  D K Shibata; N Arnheim; W J Martin
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

View more
  19 in total

Review 1.  Immunomodulation of cancer: potential use of selectively replicating agents.

Authors:  S Agha-Mohammadi; M T Lotze
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  Spontaneous but not experimental metastatic activities differentiate primary tumor-derived vs metastasis-derived mouse prostate cancer cell lines.

Authors:  S J Hall; T C Thompson
Journal:  Clin Exp Metastasis       Date:  1997-11       Impact factor: 5.150

3.  Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer.

Authors:  Liana B Guedes; Fawaz Almutairi; Michael C Haffner; Gaurav Rajoria; Zach Liu; Szczepan Klimek; Roberto Zoino; Kasra Yousefi; Rajni Sharma; Angelo M De Marzo; George J Netto; William B Isaacs; Ashley E Ross; Edward M Schaeffer; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2017-04-26       Impact factor: 12.531

Review 4.  From genomics to functions: preclinical mouse models for understanding oncogenic pathways in prostate cancer.

Authors:  Chuan Yu; Kevin Hu; Daniel Nguyen; Zhu A Wang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

Review 5.  Molecular biology of prostate cancer.

Authors:  X B Shi; P H Gumerlock; R W deVere White
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 6.  The role of the cell cycle in genitourinary carcinoma.

Authors:  T W McGarvey; S B Malkowicz
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

7.  mRTVP-1, a novel p53 target gene with proapoptotic activities.

Authors:  Chengzhen Ren; Likun Li; Alexei A Goltsov; Terry L Timme; Salahaldin A Tahir; Jianxiang Wang; Laura Garza; A Craig Chinault; Timothy C Thompson
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

8.  Molecular mechanisms involving prostate cancer racial disparity.

Authors:  David Hatcher; Garrett Daniels; Iman Osman; Peng Lee
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

9.  Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model.

Authors:  Peter Jantscheff; Vittorio Ziroli; Norbert Esser; Ralph Graeser; Jessica Kluth; Alena Sukolinskaya; Lenka A Taylor; Clemens Unger; Ulrich Massing
Journal:  Clin Exp Metastasis       Date:  2009-09-26       Impact factor: 5.150

Review 10.  Molecular basis for prostate cancer racial disparities.

Authors:  Santosh K Singh; James W Lillard; Rajesh Singh
Journal:  Front Biosci (Landmark Ed)       Date:  2017-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.